# CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia

> **NCT03275493** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd** · enrollment: 40 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia
- CD19 Positive
- Relapse
- Refractory

## Interventions

- **BIOLOGICAL:** CD19 CAR-T cells
- **BIOLOGICAL:** CD19 CAR-T cells with CRS suppression technology

## Key facts

- **NCT ID:** NCT03275493
- **Lead sponsor:** Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-07-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-05-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03275493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03275493, "CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03275493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*